Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

Introduction

The Pemitinib is identified on this website as a product containing pemigatinib 13.5 mg, an oral targeted anticancer medicine belonging to the fibroblast growth factor receptor inhibitor class.

Pemigatinib works by selectively inhibiting FGFR1, FGFR2 and FGFR3. These receptors are involved in cellular signaling pathways that regulate cell growth, survival and other biological processes.

Certain cancers develop genetic abnormalities that cause abnormal FGFR signaling. Pemigatinib is designed to target these pathways in selected patients whose conditions meet the relevant molecular and clinical requirements.

The medicine is not suitable for every cancer or every patient. Treatment requires specialist assessment, appropriate molecular testing and ongoing safety monitoring.

Product Overview

Product characteristicInformation
Product namePemitinib
Active ingredientPemigatinib
Stated strength13.5 mg
Drug classFGFR inhibitor
Target receptorsFGFR1, FGFR2 and FGFR3
Therapeutic categoryTargeted anticancer medicine
Route associated with reference productOral
Reference brandPEMAZYRE
Reference-product developerIncyte-associated development
Specific Pemitinib manufacturer–
Pemitinib regulatory status–

The actual dosage form, packaging, manufacturer and authorization status of Pemitinib should be checked against its own official product documentation.

What Is Pemigatinib?

Pemigatinib is a selective inhibitor of fibroblast growth factor receptors.

FGFR proteins are part of a family of receptors involved in signaling between cells and their surrounding environment.

Under normal circumstances, FGFR signaling participates in processes such as cell growth, tissue development and cellular repair.

In certain cancers, genetic abnormalities can alter FGFR signaling. These abnormalities may contribute to uncontrolled cell growth and survival.

Pemigatinib inhibits selected FGFR proteins and can interfere with abnormal signaling in molecularly eligible patients.

How Does Pemitinib Work?

Pemigatinib targets FGFR1, FGFR2 and FGFR3.

Its mechanism involves inhibiting the activity of these receptors and interfering with downstream signaling pathways.

The treatment objective is to reduce signaling associated with cancer-cell growth and survival in cancers that depend on abnormal FGFR activity.

The presence of an FGFR-related abnormality is important when determining treatment eligibility.

A healthcare professional must interpret the molecular test results and determine whether the patient meets the applicable prescribing requirements.

Pemitinib and Cholangiocarcinoma

One recognized clinical setting for pemigatinib is selected previously treated cholangiocarcinoma.

Cholangiocarcinoma is a cancer that develops in the bile ducts. These ducts carry bile from the liver toward the digestive system.

Some cholangiocarcinomas contain FGFR2 gene fusions or other qualifying rearrangements.

For eligible patients with unresectable locally advanced or metastatic disease, pemigatinib may be considered following previous systemic treatment, according to the applicable regulatory indication.

Molecular testing is essential because not every cholangiocarcinoma contains the required FGFR2 alteration.

Pemigatinib should not be described as a treatment for every type of bile duct cancer.

Pemitinib and FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Pemigatinib also has a U.S.-labeled indication for selected adults with relapsed or refractory myeloid/lymphoid neoplasms involving FGFR1 rearrangement.

These are uncommon blood-related cancers characterized by specific genetic abnormalities.

FGFR1 rearrangements can contribute to abnormal cellular signaling and disease development.

Treatment eligibility requires confirmation of the relevant molecular abnormality and assessment by an appropriate specialist.

This indication is jurisdiction-specific. It should not automatically be described as an approved indication in every country.

Available Strength

The Pemitinib product featured on this website is identified in a stated strength of 13.5 mg.

The established reference product PEMAZYRE is available in three tablet strengths:

  • 4.5 mg.
  • 9 mg.
  • 13.5 mg.

These are reference-product strengths and should not automatically be treated as confirmed Pemitinib packaging options.

The actual strength and dosage form of a Pemitinib product should be confirmed through its own packaging and official documentation.

How Is Pemigatinib Taken?

The established reference product is administered orally.

The prescribed treatment schedule depends on the indication.

For qualifying cholangiocarcinoma under U.S. reference-product labeling, the recommended schedule is 13.5 mg once daily for 14 consecutive days, followed by seven days without treatment, repeated in 21-day cycles.

For qualifying FGFR1-rearranged myeloid/lymphoid neoplasms, the U.S. labeled schedule is 13.5 mg once daily continuously.

Patients must follow the schedule prescribed for their specific condition.

Important Safety Considerations

Pemigatinib can cause adverse reactions that require monitoring.

Important safety considerations include:

  • Hyperphosphatemia.
  • Retinal pigment epithelial detachment.
  • Other ocular adverse reactions.
  • Nail disorders.
  • Hair loss.
  • Diarrhea.
  • Fatigue.
  • Nausea.
  • Stomatitis.
  • Skin reactions.
  • Drug interactions.
  • Embryo-fetal toxicity.

Blood phosphate monitoring and regular eye examinations are particularly important during treatment.

Who May Be Eligible for Treatment?

Treatment eligibility depends on the specific cancer diagnosis, molecular findings, previous treatment history and applicable prescribing information.

For the cholangiocarcinoma indication, the relevant FGFR2 alteration must be identified through appropriate testing.

For the U.S. FGFR1-rearranged myeloid/lymphoid neoplasm indication, the relevant FGFR1 rearrangement must be confirmed.

A specialist should review the test results, medical history and available treatment options before prescribing pemigatinib.

Product Verification

Pemitinib should be identified through its own pharmaceutical documentation.

Important details to verify include:

  • Product name.
  • Active ingredient.
  • Strength.
  • Dosage form.
  • Manufacturer.
  • Batch number.
  • Expiry date.
  • Package leaflet.
  • Regulatory authorization.

The reference product’s manufacturer or regulatory authorization should not be assumed to apply to Pemitinib.

Conclusion

The Pemitinib 13.5 mg is presented on this website as a pemigatinib product.

Pemigatinib is a targeted FGFR inhibitor used in selected molecularly defined cancer settings. Its treatment schedules, monitoring requirements and safety considerations depend on the specific indication and applicable prescribing information.

Patients should use the medicine only under specialist supervision and should confirm the identity and regulatory status of their specific product before use.